Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
To determine the maximum tolerated dose and dose-limiting toxicity of Gemcitabine plus
Albumin-bound paclitaxel (ABI-007) in patients with advanced metastatic pancreatic cancer.